ArticleDevice2026
Pressure Myography and Cardiac Flow Simulator for Mechanical Characterization of Native and Engineered Blood Vessels.
Article in Device, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Polymeric Sensors in Heart and Blood Vessel Monitoring: A Review.Sensors (Basel, Switzerland) · 2025Review
- VasoTracker 2: Open-source software and hardware for tracking blood vessel diameter and assessing vascular function.The Journal of physiology · 2025Article
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Pressure myography, which is the standard for assessing vascular mechanics and vasoreactivity, is expensive, has low throughput, and is limited to static fluid flow. Here, we developed HemoLens, an open-source 3D-printed pressure myography system for < $750. HemoLens features compact micromanipulators, incremental in-line pressure control, physiological temperature regulation, and modular pulse pressure control between normotensive and hypertensive levels. HemoLen's efficacy was demonstrated by delineation of physiological reactivity and pathological mechanical phenotypes using native mouse arteries and bioprinted acellular scaffolds. Engineered hypertensive vessels demonstrate increased burst pressure (464 mmHg) and reduced dynamic compliance reminiscent of diseased arteries. Together, HemoLens lowers the barrier to entry in pressure myography research by serving as a comprehensive low-cost system for native and engineered vessel characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.